What is Complete Cytoreduction (R0) in Ovarian Cancer?

Complete cytoreduction, often referred to in medical records as an R0 resection (pronounced “R-zero”), is the surgical removal of all macroscopically visible (visible to the naked eye) tumor deposits during ovarian cancer surgery ^[1][2]. You might also see this noted in your surgical reports as No Gross Residual Disease (NGRD) or Complete Gross Resection (CGR). This means that by the end of the operation, the surgeon cannot see or feel any remaining cancer tissue in the abdomen or pelvis. Achieving R0 is the primary goal of ovarian cancer surgery because it gives patients the best possible chance for long-term survival and delays the return of the disease ^[3][1].

Why R0 is the Primary Surgical Goal

Ovarian cancer often spreads by shedding cells throughout the abdominal cavity, creating small tumors on various organs. Because of this, the surgery to treat it—called debulking or cytoreductive surgery—is complex and extensive. The primary goal is to leave absolutely no visible tumor behind ^[1][2].

Historically, surgeons aimed for “optimal debulking,” which was defined as leaving behind individual tumor nodules that were 1 centimeter or smaller ^[3]. However, modern research has shown that patients who achieve a complete R0 resection have significantly better outcomes than those who have even a tiny amount (less than 1 cm) of visible cancer remaining ^[1]. Studies demonstrate that every 10% increase in the proportion of patients achieving complete or maximal removal of the tumor results in a measurable increase in median survival time ^[4].

How R0 Impacts Survival

The amount of tumor left behind after surgery, known as residual disease, is recognized as the single most critical prognostic factor for survival in advanced ovarian cancer ^[3][5].

Achieving an R0 resection strongly correlates with:

• Improved Overall Survival (OS): Patients who undergo a complete cytoreduction live significantly longer, on average, than those who have visible tumor remaining after surgery ^[1][6].
• Improved Progression-Free Survival (PFS): This refers to the length of time you live without the cancer growing or returning. An R0 surgery gives subsequent treatments, like chemotherapy or targeted therapies, a much smaller number of cancer cells to attack, making those treatments more effective and keeping the disease away longer ^[1][7].

Achieving Complete Cytoreduction

While R0 is always the goal, it is not always safely achievable upfront. Before surgery, your care team will use imaging (like CT or PET scans) and sometimes a minimally invasive laparoscopy to estimate how widely the cancer has spread ^[8][9]. However, the surgeon often only knows for certain if R0 is possible once you are asleep in the operating room and they can directly examine your abdomen.

The ability to remove all visible cancer depends on several factors:

• Tumor Biology and Spread: The locations of the tumors matter. If cancer has heavily involved vital structures, such as the small intestine, the diaphragm, or the major blood vessels around the liver, removing all of it safely might not be possible ^[10][11].
• Patient Health (Performance Status): Your performance status is a clinical measure of how well you can perform daily activities and care for yourself. Because attempting an R0 resection can sometimes require removing parts of the bowel, spleen, or other organs (multi-visceral resections), you must be physically strong enough to endure a long surgery and the recovery that follows ^[12][13]. It is normal to feel intimidated by this, but gynecologic oncologists are highly trained for these specific procedures. They frequently work with a multidisciplinary team of specialized surgeons in the operating room to ensure your safety. Typical hospital stays for these extensive procedures range from 4 to 10 days, depending on exactly what is removed and how quickly your bowel function returns.

If your surgeon determines that an upfront R0 resection cannot be safely achieved, they will pivot to a highly effective standard-of-care alternative. In these cases, doctors recommend starting with 3 to 4 cycles of chemotherapy (neoadjuvant chemotherapy or NACT) to shrink the tumors before operating ^[14][6]. After the tumors have shrunk, you will undergo an Interval Debulking Surgery (IDS), where the surgical goal remains exactly the same: achieving an R0 resection ^[6]. Research shows that this approach is just as effective for long-term survival while significantly reducing surgical risks and complications for patients with extensive disease ^[6][15].